Denosumab: all 207 studies that test it

Page 1 of 3. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

• Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMDNot yet recruitingNCT07772609Phase 4
• Romosozumab and Denosumab, Alone or Combined, in Postmenopausal OsteoporosisRecruitingNCT07283887Phase 4
• The Effect of Denosumab on Muscle and Strength and Insulin SensitivityRecruitingNCT07271771Phase 4
• A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®RecruitingNCT07062978Phase 3
• RANKL Inhibition to Combat Sarcopenia in Hip Fracture PatientsNot yet recruitingNCT07056478Phase 3
• RANK-ligand Inhibition to Combat Sarcopenia With Underlying OsteoporosisRecruitingNCT06643780Phase 4
• Denosumab for Type 1 DiabetesRecruitingNCT06524960Phase 1/2
• Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related OutcomesRecruitingNCT06154707Phase 3
• Preserving Geriatric Muscle With an Osteoporosis MedicationRecruitingNCT06118905Phase 4
• DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)RecruitingNCT05966064Phase 4
• Denosumab Treatment in CKD Patients at High Risk of FractureRecruitingNCT05692297Not applicable
• Denosumab Biosimilar Injection in Post Menopausal Women With OsteoporosisRecruitingNCT05419427Phase 3
• Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill AdultsRecruitingNCT04608630Phase 2
• The DENOCHARCOT TrialRecruitingNCT04547348Phase 3
• Markers of Osteoporosis in Cystic FibrosisRecruitingNCT03921060Phase 4
• A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With OsteoporosisCompletedNCT04757376Phase 3Results posted
• A Study to Test if TVB-009P is Effective in Relieving Postmenopausal OsteoporosisCompletedNCT04729621Phase 3Results posted
• Denosumab to Prevent High-Turnover Bone Loss After Bariatric SurgeryCompletedNCT04087096Phase 4Results posted
• RANKL Inhibition and Mammographic Breast DensityActive, not recruitingNCT04067726Phase 2Results posted
• Bone Modeling Effects of Combined Anabolic/Antiresorptive AdministrationCompletedNCT04026256Phase 4Results posted
• The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant RecipientsTerminatedNCT03960554Phase 2Results posted
• Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell TransplantCompletedNCT03925532Phase 2Results posted
• Denosumab for Smoldering Multiple MyelomaCompletedNCT03839459Phase 2Results posted
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal WomenCompletedNCT03822078Phase 1Results posted
• Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis ImperfectaTerminatedNCT03638128Phase 3Results posted
• Denosumab + PD-1 in Subjects With Stage III/ IV MelanomaCompletedNCT03620019Phase 2Results posted
• Therapy of the Skeletal Disease of Type 2 Diabetes With DenosumabTerminatedNCT03457818Phase 2Results posted
• Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-OophorectomyTerminatedNCT03382574Early Phase 1Results posted
• Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004CompletedNCT03301857Phase 4Results posted
• Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot StudyCompletedNCT03292146Phase 3Results posted
• Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot NeuroarthropathyCompletedNCT03174366Phase 3Results posted
• Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced OsteoporosisCompletedNCT03164928Phase 3Results posted
• Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor CellsTerminatedNCT03070002Phase 2Results posted
• Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.CompletedNCT03027557Phase 3Results posted
• Denosumab In Addition To Intense Urate-Lowering Therapy for Bone ErosionsCompletedNCT02903446Phase 2Results posted
• RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger JointsCompletedNCT02771860Phase 2Results posted
• Preventing Osteoporosis Using DenosumabCompletedNCT02753283Phase 4Results posted
• Denosumab and MRI Breast ImagingCompletedNCT02613416Phase 2Results posted
• Denosumab in Treating Patients With Recurrent or Refractory OsteosarcomaCompletedNCT02470091Phase 2Results posted
• Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast CancerCompletedNCT02366130Phase 2Results posted
• Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OITerminatedNCT02352753Phase 3Results posted
• Denosumab and Teriparatide Study (DATA-HD and DATA-EX)CompletedNCT02176382Phase 4Results posted
• A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With OsteoporosisCompletedNCT02157948Phase 3Results posted
• Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapyTerminatedNCT02129699Phase 3Results posted
• Effect of Denosumab on Cellular Biomarkers in the Human BreastCompletedNCT02099461Phase 1Results posted
• Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug ProductCompletedNCT02053753Phase 1Results posted
• Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOPCompletedNCT02049866Phase 2Results posted
• Denosumab China Phase III StudyCompletedNCT02014467Phase 3Results posted
• AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) TreatmentCompletedNCT01973569Not applicableResults posted
• Denosumab for Breast Cancer With Bone MetsTerminatedNCT01952054Phase 2Results posted
• Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung CancerCompletedNCT01951586Phase 2Results posted
• A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid TumorsCompletedNCT01920568Phase 3Results posted
• Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous DoseCompletedNCT01869686Phase 1Results posted
• Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate CancerCompletedNCT01824342Phase 3Results posted
• Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone ResorptionCompletedNCT01750086Phase 4Results posted
• Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With OsteoporosisCompletedNCT01732770Phase 4Results posted
• Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking GlucocorticoidsCompletedNCT01575873Phase 3Results posted
• Denosumab in Primary HyperparathyroidismTerminatedNCT01558115Phase 4Results posted
• Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast CancerTerminatedNCT01545648Phase 2Results posted
• A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of DenosumabCompletedNCT01495000Phase 3Results posted
• Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on DialysisCompletedNCT01464931Phase 1Results posted
• A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of DenosumabCompletedNCT01457950Phase 3Results posted
• Open-Label Access Protocol of Denosumab for Subjects With Advanced CancerCompletedNCT01419717Phase 3Results posted
• Denosumab for Prevention of Osteoporosis in Renal Transplant RecipientsCompletedNCT01377467Phase 3Results posted
• Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple MyelomaCompletedNCT01345019Phase 3Results posted
• Effects of Denosumab on the Pharmacokinetics of EtanerceptTerminatedNCT01294397Phase 1Results posted
• The Effects of Denosumab on the Pharmacokinetics (PK) of MidazolamCompletedNCT01221727Phase 1Results posted
• Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)TerminatedNCT01077154Phase 3Results posted
• Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With OsteoporosisCompletedNCT00980174Phase 3Results posted
• Open Label Extension to SRE Studies in United Kingdom and Czech Republic OnlyCompletedNCT00950911Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly BisphosphonatesCompletedNCT00936897Phase 3Results posted
• Denosumab, Teriparatide or Both for the Treatment of Postmenopausal OsteoporosisCompletedNCT00926380Phase 2Results posted
• Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone LossCompletedNCT00925600Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate TherapyCompletedNCT00919711Phase 3Results posted
• Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral DensityCompletedNCT00896532Phase 2Results posted
• Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumCompletedNCT00896454Phase 2Results posted
• A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With DenosumabCompletedNCT00890981Phase 3Results posted
• Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate CancerCompletedNCT00838201Phase 3Results posted
• Study of Denosumab in Subjects With Giant Cell Tumor of BoneCompletedNCT00680992Phase 2Results posted
• Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With OsteoporosisCompletedNCT00680953Phase 3Results posted
• Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyCompletedNCT00556374Phase 3Results posted
• Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of OsteoporosisCompletedNCT00523341Phase 3Results posted
• Denosumab Adherence Preference Satisfaction StudyCompletedNCT00518531Phase 3Results posted
• A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral DensityCompletedNCT00515463Phase 3Results posted
• Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of BoneCompletedNCT00396279Phase 2Results posted
• Study of Transitioning From Alendronate to DenosumabCompletedNCT00377819Phase 3Results posted
• Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.CompletedNCT00330759Phase 3Results posted
• A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.CompletedNCT00330460Phase 3Results posted
• An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral DensityCompletedNCT00325468Phase 3Results posted
• Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate CancerCompletedNCT00321620Phase 3Results posted
• A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.CompletedNCT00321464Phase 3Results posted
• A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic SubjectsCompletedNCT00306189Phase 2Results posted
• A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral DensityCompletedNCT00293813Phase 2Results posted
• Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate CancerCompletedNCT00286091Phase 3Results posted
• Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - DenosumabCompletedNCT00259740Phase 2Results posted
• Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid ArthritisCompletedNCT00095498Phase 2Results posted
• Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast CancerCompletedNCT00091832Phase 2Results posted
• Study to Evaluate AMG 162 in the Prevention of Postmenopausal OsteoporosisCompletedNCT00091793Phase 3Results posted
• A Study to Evaluate Denosumab in the Treatment of Postmenopausal OsteoporosisCompletedNCT00089791Phase 3Results posted
• AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate CancerCompletedNCT00089674Phase 3Results posted

← Denosumab overview